{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:21:10Z","timestamp":1793154070129,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Methamphetamine\/amphetamine use has sharply increased among people with opioid use disorder (OUD). It is therefore important to understand whether and how use of these substances may impact receipt of, and outcomes associated with, medications for OUD (MOUD). This systematic review identified studies that examined associations between methamphetamine\/amphetamine use or use disorder and 3 classes of outcomes: (1) receipt of MOUD, (2) retention in MOUD, and (3) opioid abstinence during MOUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched 3 databases (PubMed\/MEDLINE, PsycINFO, CINAHL Complete) from 1\/1\/2000 to 7\/28\/2020 using key words and subject headings, and hand-searched reference lists of included articles. English-language studies of people with documented OUD\/opioid use that reported a quantitative association between methamphetamine\/amphetamine use or use disorder and an outcome of interest were included. Study data were extracted using a standardized template, and risk of bias was assessed for each study. Screening, inclusion, data extraction and bias assessment were conducted independently by 2 authors. Study characteristics and findings were summarized for each class of outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-nine studies met inclusion criteria. Studies generally found that methamphetamine\/amphetamine use or use disorder was negatively associated with receiving methadone and buprenorphine; 2 studies suggested positive associations with receiving naltrexone. Studies generally found negative associations with retention; most studies finding no association had small samples, and these studies tended to examine shorter retention timeframes and describe provision of adjunctive services to address substance use. Studies generally found negative associations with opioid abstinence during treatment among patients receiving methadone or sustained-release naltrexone implants, though observed associations may have been confounded by other polysubstance use. Most studies examining opioid abstinence during other types of MOUD treatment had small samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, existing research suggests people who use methamphetamine\/amphetamines may have lower receipt of MOUD, retention in MOUD, and opioid abstinence during MOUD. Future research should examine how specific policies and treatment models impact MOUD outcomes for these patients, and seek to understand the perspectives of MOUD providers and people who use both opioids and methamphetamine\/amphetamines. Efforts to improve MOUD care and overdose prevention strategies are needed for this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-021-00266-2","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T14:06:19Z","timestamp":1633961179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["The impact of methamphetamine\/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-7692","authenticated-orcid":false,"given":"Madeline C.","family":"Frost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Lampert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Iles-Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"266_CR1","volume-title":"2019 National survey on drug use and health: detailed tables","author":"Center for Behavioral Health Statistics and Quality","year":"2020","unstructured":"Center for Behavioral Health Statistics and Quality. 2019 National survey on drug use and health: detailed tables. Rockville: Substance Abuse and Mental Health Services Administration; 2020."},{"issue":"6","key":"266_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","volume":"70","author":"CL Mattson","year":"2021","unstructured":"Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20132019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"266_CR3","unstructured":"Centers for Disease Control and Prevention Health Alert Network. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. 2020. https:\/\/emergency.cdc.gov\/han\/2020\/han00438.asp?ACSTrackingID=USCDC_511-DM44961&ACSTrackingLabel=HAN%20438%20-%20General%20Public&deliveryName=USCDC_511-DM44961. Accessed 12 Jan 2020."},{"key":"266_CR4","unstructured":"Ahmad FBRL, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2021. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm. Accessed 17 Mar 2021."},{"key":"266_CR5","doi-asserted-by":"publisher","first-page":"108176","DOI":"10.1016\/j.drugalcdep.2020.108176","volume":"214","author":"S Slavova","year":"2020","unstructured":"Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214:108176.","journal-title":"Drug Alcohol Depend"},{"issue":"16","key":"266_CR6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jama.2020.17477","volume":"324","author":"TA Ochalek","year":"2020","unstructured":"Ochalek TA, Cumpston KL, Wills BK, Gal TS, Moeller FG. Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic. JAMA. 2020;324(16):1673\u20134.","journal-title":"JAMA"},{"key":"266_CR7","unstructured":"American Medical Association Advocacy Resource Center. Issue brief: reports of increases in opioid- and other drug-related overdose and other concerns during COVID pandemic. 2020. https:\/\/www.ama-assn.org\/system\/files\/2020-10\/issue-brief-increases-in-opioid-related-overdose.pdf. Accessed 20 Oct 2020."},{"issue":"12","key":"266_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"L Degenhardt","year":"2018","unstructured":"Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987\u20131012.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"266_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","volume":"76","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiat. 2019;76(2):208\u201316.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"266_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/add.13193","volume":"111","author":"M Pierce","year":"2016","unstructured":"Pierce M, Bird SM, Hickman M, Marsden J, Dunn G, Jones A, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction. 2016;111(2):298\u2013308.","journal-title":"Addiction"},{"issue":"2","key":"266_CR11","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"266_CR12","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/add.14991","volume":"115","author":"N Krawczyk","year":"2020","unstructured":"Krawczyk N, Mojtabai R, Stuart EA, Fingerhood M, Agus D, Lyons BC, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9):1683\u201394.","journal-title":"Addiction"},{"issue":"3","key":"266_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/08897077.2020.1787299","volume":"41","author":"AJ Gordon","year":"2020","unstructured":"Gordon AJ, Drexler K, Hawkins EJ, Burden J, Codell NK, Mhatre-Owens A, et al. Stepped care for opioid use disorder train the trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abus. 2020;41(3):275\u201382.","journal-title":"Subst Abus"},{"issue":"1","key":"266_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13722-021-00218-w","volume":"16","author":"CI Campbell","year":"2021","unstructured":"Campbell CI, Saxon AJ, Boudreau DM, Wartko PD, Bobb JF, Lee AK, et al. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. Addict Sci Clin Pract. 2021;16(1):9.","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"266_CR15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1080\/08897077.2019.1635557","volume":"41","author":"JE Hood","year":"2020","unstructured":"Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington. Subst Abus. 2020;41(3):356\u201364.","journal-title":"Subst Abus"},{"issue":"2","key":"266_CR16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2105\/AJPH.2019.305412","volume":"110","author":"TJ Cicero","year":"2020","unstructured":"Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244\u201350.","journal-title":"Am J Public Health"},{"key":"266_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","volume":"193","author":"MS Ellis","year":"2018","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14\u201320.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"266_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/add.14812","volume":"115","author":"CM Jones","year":"2020","unstructured":"Jones CM, Underwood N, Compton WM. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008\u201317. Addiction. 2020;115(2):347\u201353.","journal-title":"Addiction"},{"key":"266_CR19","doi-asserted-by":"publisher","first-page":"107592","DOI":"10.1016\/j.drugalcdep.2019.107592","volume":"204","author":"JC Strickland","year":"2019","unstructured":"Strickland JC, Havens JR, Stoops WW. A nationally representative analysis of \u201ctwin epidemics\u201d: rising rates of methamphetamine use among persons who use opioids. Drug Alcohol Depend. 2019;204:107592.","journal-title":"Drug Alcohol Depend"},{"key":"266_CR20","unstructured":"United Nations Office of Drugs and Crime. World Drug Report 2020. 2020. https:\/\/wdr.unodc.org\/wdr2020\/index.html. Accessed 8 Mar 2021."},{"issue":"2","key":"266_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1037\/0033-2909.134.2.301","volume":"134","author":"BD Homer","year":"2008","unstructured":"Homer BD, Solomon TM, Moeller RW, Mascia A, DeRaleau L, Halkitis PN. Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull. 2008;134(2):301\u201310.","journal-title":"Psychol Bull"},{"issue":"1","key":"266_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/epirev\/mxaa005","volume":"42","author":"CT Blondino","year":"2020","unstructured":"Blondino CT, Gormley MA, Taylor DDH, Lowery E, Clifford JS, Burkart B, et al. The influence of co-occurring substance use on the effectiveness of opiate treatment programs according to intervention type. Epidemiol Rev. 2020;42(1):57\u201378.","journal-title":"Epidemiol Rev"},{"issue":"7","key":"266_CR23","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"6","key":"266_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","volume":"144","author":"JA Hayden","year":"2006","unstructured":"Hayden JA, C\u00f4t\u00e9 P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144(6):427\u201337.","journal-title":"Ann Intern Med"},{"key":"266_CR25","volume-title":"Covidence systematic review software","author":"Veritas Health Innovation","year":"2017","unstructured":"Veritas Health Innovation. Covidence systematic review software. Melbourne: Veritas Health Innovation; 2017."},{"issue":"5","key":"266_CR26","first-page":"360","volume":"37","author":"AJ Viera","year":"2005","unstructured":"Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360\u20133.","journal-title":"Fam Med"},{"issue":"3","key":"266_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/15504263.2017.1325033","volume":"13","author":"B Shiner","year":"2017","unstructured":"Shiner B, Leonard Westgate C, Bernardy NC, Schnurr PP, Watts BV. Trends in opioid use disorder diagnoses and medication treatment among veterans with posttraumatic stress disorder. J Dual Diagn. 2017;13(3):201\u201312.","journal-title":"J Dual Diagn"},{"issue":"11","key":"266_CR28","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1111\/add.14733","volume":"114","author":"TG Rhee","year":"2019","unstructured":"Rhee TG, Rosenheck RA. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States? Addiction. 2019;114(11):1992\u20139.","journal-title":"Addiction"},{"key":"266_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.drugalcdep.2017.07.004","volume":"179","author":"L Michel","year":"2017","unstructured":"Michel L, Des Jarlais DC, Duong TH, Khuat THO, Pham MK, Peries M, et al. Intravenous heroin use in Haiphong, Vietnam: need for comprehensive care including methamphetamine use-related interventions. Drug Alcohol Depend. 2017;179:198\u2013204.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"266_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/BF02287379","volume":"31","author":"D Deck","year":"2004","unstructured":"Deck D, Carlson MJ. Access to publicly funded methadone maintenance treatment in two western states. J Behav Health Serv Res. 2004;31(2):164\u201377.","journal-title":"J Behav Health Serv Res"},{"issue":"1","key":"266_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jsat.2011.10.022","volume":"43","author":"N Fairbairn","year":"2012","unstructured":"Fairbairn N, Hayashi K, Kaplan K, Suwannawong P, Qi J, Wood E, et al. Factors associated with methadone treatment among injection drug users in Bangkok. Thailand J Subst Abuse Treat. 2012;43(1):108\u201313.","journal-title":"Thailand J Subst Abuse Treat"},{"issue":"1","key":"266_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.drugalcdep.2013.05.022","volume":"133","author":"L Gjersing","year":"2013","unstructured":"Gjersing L, Bretteville-Jensen AL. Is opioid substitution treatment beneficial if injecting behaviour continues? Drug Alcohol Depend. 2013;133(1):121\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"266_CR33","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1080\/10826084.2020.1765805","volume":"55","author":"R Daniulaityte","year":"2020","unstructured":"Daniulaityte R, Silverstein SM, Crawford TN, Martins SS, Zule W, Zaragoza AJ, et al. Methamphetamine use and its correlates among individuals with opioid use disorder in a Midwestern US city. Subst Use Misuse. 2020;55(11):1781\u20139.","journal-title":"Subst Use Misuse"},{"key":"266_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","volume":"85","author":"JR Morgan","year":"2018","unstructured":"Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90\u20136.","journal-title":"J Subst Abuse Treat"},{"key":"266_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jsat.2016.09.006","volume":"71","author":"MT Hall","year":"2016","unstructured":"Hall MT, Wilfong J, Huebner RA, Posze L, Willauer T. Medication-assisted treatment improves child permanency outcomes for opioid-using families in the child welfare system. J Subst Abuse Treat. 2016;71:63\u20137.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"266_CR36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jsat.2010.05.001","volume":"39","author":"T Pettes","year":"2010","unstructured":"Pettes T, Wood E, Guillemi S, Lai C, Montaner J, Kerr T. Methadone use among HIV-positive injection drug users in a Canadian setting. J Subst Abuse Treat. 2010;39(2):174\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"266_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/08897077.2019.1640831","volume":"41","author":"A Manhapra","year":"2020","unstructured":"Manhapra A, Stefanovics E, Rosenheck R. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: who gets what? Subst Abus. 2020;41(1):110\u201320.","journal-title":"Subst Abus"},{"issue":"3","key":"266_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0376-8716(00)00147-2","volume":"61","author":"X Thirion","year":"2001","unstructured":"Thirion X, Micallef J, Barrau K, Djezzar S, Lambert H, Sanmarco JL, et al. Recent evolution in opiate dependence in France during generalisation of maintenance treatments. Drug Alcohol Depend. 2001;61(3):281\u20135.","journal-title":"Drug Alcohol Depend"},{"key":"266_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jsat.2019.10.005","volume":"109","author":"JI Tsui","year":"2020","unstructured":"Tsui JI, Mayfield J, Speaker EC, Yakup S, Ries R, Funai H, et al. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. J Subst Abuse Treat. 2020;109:80\u20135.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"266_CR40","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000345229","volume":"19","author":"I Skeie","year":"2013","unstructured":"Skeie I, Brekke M, Clausen T, Gossop M, Lindbaek M, Reinertsen E, et al. Increased somatic morbidity in the first year after leaving opioid maintenance treatment: results from a Norwegian cohort study. Eur Addict Res. 2013;19(4):194\u2013201.","journal-title":"Eur Addict Res"},{"issue":"1","key":"266_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79\u201387.","journal-title":"Addiction"},{"issue":"4","key":"266_CR42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/09540121.2016.1259452","volume":"29","author":"D Liu","year":"2017","unstructured":"Liu D, Gu J, Xu H, Hao C, Jiao M, Zhang X, et al. Club drugs and alcohol abuse predicted dropout and poor adherence among methadone maintenance treatment patients in Guangzhou, China. AIDS Care. 2017;29(4):458\u201363.","journal-title":"AIDS Care"},{"issue":"5","key":"266_CR43","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1360-0443.2009.02538.x","volume":"104","author":"CJ Banta-Green","year":"2009","unstructured":"Banta-Green CJ, Maynard C, Koepsell TD, Wells EA, Donovan DM. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users. Addiction. 2009;104(5):775\u201383.","journal-title":"Addiction"},{"key":"266_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jsat.2018.08.009","volume":"94","author":"A Lo","year":"2018","unstructured":"Lo A, Kerr T, Hayashi K, Milloy MJ, Nosova E, Liu Y, et al. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs. J Subst Abuse Treat. 2018;94:41\u20136.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"266_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/10550880802324382","volume":"27","author":"E Peles","year":"2008","unstructured":"Peles E, Linzy S, Kreek M, Adelson M. One-year and cumulative retention as predictors of success in methadone maintenance treatment: a comparison of two clinics in the United States and Israel. J Addict Dis. 2008;27(4):11\u201325.","journal-title":"J Addict Dis"},{"issue":"1","key":"266_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF02287327","volume":"32","author":"D Deck","year":"2005","unstructured":"Deck D, Carlson MJ. Retention in publicly funded methadone maintenance treatment in two Western States. J Behav Health Serv Res. 2005;32(1):43\u201360.","journal-title":"J Behav Health Serv Res"},{"issue":"10","key":"266_CR47","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.addbeh.2007.01.010","volume":"32","author":"M Schiff","year":"2007","unstructured":"Schiff M, Levit S, Moreno RC. Retention and illicit drug use among methadone patients in Israel: a gender comparison. Addict Behav. 2007;32(10):2108\u201319.","journal-title":"Addict Behav"},{"issue":"3","key":"266_CR48","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jsat.2014.04.006","volume":"47","author":"Z Schuman-Olivier","year":"2014","unstructured":"Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat. 2014;47(3):202\u201312.","journal-title":"J Subst Abuse Treat"},{"issue":"7","key":"266_CR49","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/ajad.12437","volume":"25","author":"N Kumar","year":"2016","unstructured":"Kumar N, Stowe ZN, Han X, Mancino MJ. Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program. Am J Addict. 2016;25(7):542\u20138.","journal-title":"Am J Addict"},{"issue":"4","key":"266_CR50","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1037\/adb0000090","volume":"29","author":"SL Proctor","year":"2015","unstructured":"Proctor SL, Copeland AL, Kopak AM, Hoffmann NG, Herschman PL, Polukhina N. Predictors of patient retention in methadone maintenance treatment. Psychol Addict Behav. 2015;29(4):906\u201317.","journal-title":"Psychol Addict Behav"},{"issue":"10","key":"266_CR51","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1037\/ccp0000410","volume":"87","author":"DE Logan","year":"2019","unstructured":"Logan DE, Lavoie AM, Zwick WR, Kunz K, Bumgardner MA, Molina Y. Integrating addiction medicine into rural primary care: Strategies and initial outcomes. J Consult Clin Psychol. 2019;87(10):952\u201361.","journal-title":"J Consult Clin Psychol"},{"key":"266_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jsat.2014.12.010","volume":"54","author":"E Peles","year":"2015","unstructured":"Peles E, Schreiber S, Linzy S, Domani Y, Adelson M. Differences in methylphenidate abuse rates among methadone maintenance treatment patients in two clinics. J Subst Abuse Treat. 2015;54:44\u20139.","journal-title":"J Subst Abuse Treat"},{"key":"266_CR53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jsat.2017.05.010","volume":"79","author":"D Hui","year":"2017","unstructured":"Hui D, Weinstein ZM, Cheng DM, Quinn E, Kim H, Labelle C, et al. Very early disengagement and subsequent re-engagement in primary care office based opioid treatment (OBOT) with buprenorphine. J Subst Abuse Treat. 2017;79:12\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"266_CR54","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12887-018-1137-4","volume":"18","author":"BP Smyth","year":"2018","unstructured":"Smyth BP, Elmusharaf K, Cullen W. Opioid substitution treatment and heroin dependent adolescents: reductions in heroin use and treatment retention over twelve months. BMC Pediatr. 2018;18(1):151.","journal-title":"BMC Pediatr"},{"issue":"6","key":"266_CR55","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/ajad.12553","volume":"26","author":"A Manhapra","year":"2017","unstructured":"Manhapra A, Petrakis I, Rosenheck R. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. Am J Addict. 2017;26(6):572\u201380.","journal-title":"Am J Addict"},{"issue":"7","key":"266_CR56","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1176\/appi.ps.201700363","volume":"69","author":"A Manhapra","year":"2018","unstructured":"Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69(7):768\u201376.","journal-title":"Psychiatr Serv"},{"issue":"2","key":"266_CR57","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/02791072.2014.901587","volume":"46","author":"WL White","year":"2014","unstructured":"White WL, Campbell MD, Spencer RD, Hoffman HA, Crissman B, DuPont RL. Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention. J Psychoactive Drugs. 2014;46(2):114\u201322.","journal-title":"J Psychoactive Drugs"},{"key":"266_CR58","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pnpbp.2018.01.008","volume":"83","author":"CC Liu","year":"2018","unstructured":"Liu CC, Fang CP, Liu TH, Kuo HW, Liu SC, Wang SC, et al. APBB2 is associated with amphetamine use and plasma beta-amyloids in patients receiving methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2018;83:92\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"266_CR59","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.drugpo.2018.02.020","volume":"55","author":"T Hoang","year":"2018","unstructured":"Hoang T, Nguyen H, Shiraishi RW, Nguyen M, Bingham T, Nguyen D, et al. Factors associated with concurrent heroin use among patients on methadone maintenance treatment in Vietnam: a 24-month retrospective analysis of a nationally representative sample. Int J Drug Policy. 2018;55:113\u201320.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"266_CR60","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/j.1360-0443.2010.03031.x","volume":"105","author":"N Kun\u00f8e","year":"2010","unstructured":"Kun\u00f8e N, Lobmaier P, Vederhus JK, Hjerkinn B, Gossop M, Hegstad S, et al. Challenges to antagonist blockade during sustained-release naltrexone treatment. Addiction. 2010;105(9):1633\u20139.","journal-title":"Addiction"},{"issue":"6","key":"266_CR61","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3109\/14659891.2015.1118564","volume":"21","author":"SL Proctor","year":"2016","unstructured":"Proctor SL, Copeland AL, Kopak AM, Hoffmann NG, Herschman PL, Polukhina N. Outcome predictors for patients receiving methadone maintenance treatment: findings from a retrospective multi-site study. J Subst Use. 2016;21(6):601\u201313.","journal-title":"J Subst Use"},{"issue":"4","key":"266_CR62","doi-asserted-by":"publisher","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","volume":"74","author":"JS Potter","year":"2013","unstructured":"Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, et al. Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs. 2013;74(4):605\u201313.","journal-title":"J Stud Alcohol Drugs"},{"issue":"6","key":"266_CR63","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1465-3362.2009.00064.x","volume":"28","author":"R Senbanjo","year":"2009","unstructured":"Senbanjo R, Wolff K, Marshall EJ, Strang J. Persistence of heroin use despite methadone treatment: poor coping self-efficacy predicts continued heroin use. Drug Alcohol Rev. 2009;28(6):608\u201315.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"266_CR64","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/08897077.2015.1065541","volume":"37","author":"T Abrahamsson","year":"2016","unstructured":"Abrahamsson T, Widinghoff C, Lilliebladh A, Gedeon C, Nilvall K, Hakansson A. Interim buprenorphine treatment in opiate dependence: a pilot effectiveness study. Subst Abus. 2016;37(1):104\u20139.","journal-title":"Subst Abus"},{"issue":"18","key":"266_CR65","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889\u2013900.","journal-title":"JAMA"},{"issue":"2","key":"266_CR66","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa2020214","volume":"384","author":"MH Trivedi","year":"2021","unstructured":"Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140\u201353.","journal-title":"N Engl J Med"},{"issue":"12","key":"266_CR67","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1111\/add.14755","volume":"114","author":"B Chan","year":"2019","unstructured":"Chan B, Freeman M, Kondo K, Ayers C, Montgomery J, Paynter R, et al. Pharmacotherapy for methamphetamine\/amphetamine use disorder-a systematic review and meta-analysis. Addiction. 2019;114(12):2122\u201336.","journal-title":"Addiction"},{"key":"266_CR68","unstructured":"Department of Veterans Affairs. VA\/DoD clinical practice guideline for the management of substance use disorders. 2015. http:\/\/www.healthquality.va.gov\/guidelines\/MH\/sud\/VADoDSUDCPGRevised22216.pdf. Accessed 4 Oct 2018."},{"key":"266_CR69","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2019.03.009","volume":"200","author":"BE Payne","year":"2019","unstructured":"Payne BE, Klein JW, Simon CB, James JR, Jackson SL, Merrill JO, et al. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program. Drug Alcohol Depend. 2019;200:71\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"266_CR70","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/02791072.2019.1578445","volume":"51","author":"Z Alammehrjerdi","year":"2019","unstructured":"Alammehrjerdi Z, Briggs NE, Biglarian A, Mokri A, Dolan K. A randomized controlled trial of brief cognitive behavioral therapy for regular methamphetamine use in methadone treatment. J Psychoactive Drugs. 2019;51(3):280\u20139.","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"266_CR71","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/archpsyc.63.2.201","volume":"63","author":"JM Peirce","year":"2006","unstructured":"Peirce JM, Petry NM, Stitzer ML, Blaine J, Kellogg S, Satterfield F, et al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network Study. Arch Gen Psychiatry. 2006;63(2):201\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"266_CR72","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.1969","author":"HA Bol\u00edvar","year":"2021","unstructured":"Bol\u00edvar HA, Klemperer EM, Coleman SRM, DeSarno M, Skelly JM, Higgins ST. Contingency management for patients receiving medication for opioid use disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2021. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.1969.","journal-title":"JAMA Psychiatry"},{"key":"266_CR73","doi-asserted-by":"publisher","first-page":"107799","DOI":"10.1016\/j.drugalcdep.2019.107799","volume":"207","author":"CJ Banta-Green","year":"2020","unstructured":"Banta-Green CJ, Williams JR, Sears JM, Floyd AS, Tsui JI, Hoeft TJ. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder. Drug Alcohol Depend. 2020;207:107799.","journal-title":"Drug Alcohol Depend"},{"issue":"16","key":"266_CR74","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jama.2015.3474","volume":"313","author":"G D'Onofrio","year":"2015","unstructured":"D\u2019Onofrio G, O\u2019Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636\u201344.","journal-title":"JAMA"},{"issue":"1","key":"266_CR75","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/ADM.0000000000000360","volume":"12","author":"HK Knudsen","year":"2018","unstructured":"Knudsen HK, Lofwall MR, Walsh SL, Havens JR, Studts JL. Physicians\u2019 decision-making when implementing buprenorphine with new patients: conjoint analyses of data from a cohort of current prescribers. J Addict Med. 2018;12(1):31\u20139.","journal-title":"J Addict Med"},{"issue":"3","key":"266_CR76","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jsat.2013.09.002","volume":"46","author":"CA Green","year":"2014","unstructured":"Green CA, McCarty D, Mertens J, Lynch FL, Hilde A, Firemark A, et al. A qualitative study of the adoption of buprenorphine for opioid addiction treatment. J Subst Abuse Treat. 2014;46(3):390\u2013401.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"266_CR77","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/ADM.0000000000000426","volume":"12","author":"MC Frost","year":"2018","unstructured":"Frost MC, Williams EC, Kingston S, Banta-Green CJ. Interest in getting help to reduce or stop substance use among syringe exchange clients who use opioids. J Addict Med. 2018;12(6):428\u201334.","journal-title":"J Addict Med"},{"key":"266_CR78","doi-asserted-by":"publisher","first-page":"108428","DOI":"10.1016\/j.drugalcdep.2020.108428","volume":"219","author":"E Coupet Jr","year":"2021","unstructured":"Coupet E Jr, D\u2019Onofrio G, Chawarski M, Edelman EJ, O\u2019Connor PG, Owens P, et al. Emergency department patients with untreated opioid use disorder: a comparison of those seeking versus not seeking referral to substance use treatment. Drug Alcohol Depend. 2021;219:108428.","journal-title":"Drug Alcohol Depend"},{"key":"266_CR79","doi-asserted-by":"publisher","first-page":"102934","DOI":"10.1016\/j.drugpo.2020.102934","volume":"85","author":"PK Valente","year":"2020","unstructured":"Valente PK, Bazzi AR, Childs E, Salhaney P, Earlywine J, Olson J, et al. Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the US Northeast. Int J Drug Policy. 2020;85:102934.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"266_CR80","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/dar.13049","volume":"39","author":"R McNeil","year":"2020","unstructured":"McNeil R, Puri N, Boyd J, Mayer S, Hayashi K, Small W. Understanding concurrent stimulant use among people on methadone: a qualitative study. Drug Alcohol Rev. 2020;39(3):209\u201315.","journal-title":"Drug Alcohol Rev"},{"key":"266_CR81","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.drugalcdep.2014.10.012","volume":"145","author":"C Potier","year":"2014","unstructured":"Potier C, Lapr\u00e9vote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48\u201368.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"266_CR82","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/add.13326","volume":"111","author":"R McDonald","year":"2016","unstructured":"McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111(7):1177\u201387.","journal-title":"Addiction"},{"issue":"6","key":"266_CR83","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamainternmed.2019.0272","volume":"179","author":"R Abouk","year":"2019","unstructured":"Abouk R, Pacula RL, Powell D. Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Intern Med. 2019;179(6):805\u201311.","journal-title":"JAMA Intern Med"},{"key":"266_CR84","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1136\/bmj.f174","volume":"346","author":"AY Walley","year":"2013","unstructured":"Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:174.","journal-title":"BMJ"},{"issue":"4","key":"266_CR85","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280\u20136.","journal-title":"Ann Intern Med"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-021-00266-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-021-00266-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-021-00266-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T14:42:56Z","timestamp":1633963376000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-021-00266-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["266"],"URL":"https:\/\/doi.org\/10.1186\/s13722-021-00266-2","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"assertion":[{"value":"10 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The opinions expressed in this work are the authors\u2019 and do not necessarily reflect those of the institutions, funders, the Department of Veterans Affairs, or the United States Government.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"62"}}